Individuals Discontinuing Anti-Obesity Medications Put On Pounds Far More Rapidly Compared to Those on Conventional Diets

A recent study suggests that patients who stop using popular slimming jabs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens.

Published data in a major health publication shows that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.

"Users using such treatments must be informed of the danger of quick rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.

Such speed of recovery suggests a reversion to pre-treatment weight within about one and a half years.

Weighing Approaches

The analysis, which examined dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting.

Researchers note that individuals who shed pounds through diet and exercise typically see a slower creep back—approximately 100 grams monthly—post-intervention.

Explaining the Rapid Regain

Nutrition scientists believe the mode of action of the injections explains the heightened weight return.

The injections copy a body's own chemical called GLP-1, which controls appetite.

"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.

"Stopping of this medication results in hunger is no longer kept in check, making binge eating much more probable."

An Ongoing Condition?

The NHS recommend the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.

Professionals contend that, due to the high risk of weight regain, the therapy is often ongoing.

This view is reinforced by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like hypertension.

User Testimonies

Users who have stopped the jabs report a sudden return of cravings.

"I experienced something activating and you're instantly starving," described a patient.

This difficulty is worsened if users have not adopted sustainable lifestyle or habit changes during treatment.

Significant Adoption

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.

• Adoption is more common among females than men.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Finally, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss likely depends on integrated behavioural changes.